AstraZeneca Sees Strength In Small Molecules, Starts Building Oncology Franchises

With its first oncology approval in 15 years, an imminent submission for its next cancer drug and a slew of trials starting by the end of the year, AstraZeneca is starting to show how oncology will be a growth platform.